Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at UC Irvine
- Dates
- study startedestimated completion
Description
Summary
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rigel Pharmaceuticals
- ID
- NCT04629703
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 308 study participants
- Last Updated